Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 4/20 | 0.57 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALPG | P10696 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431925 | 0.87 | CDK1 (0.60) | MEN1KMT2ARAB9ANPC1CYP1A2 | |
| SCHEMBL18559680 | 0.86 | MEN1 (0.56) | MEN1KMT2ARAB9ANPC1CYP1A2 | |
| SCHEMBL857502 | 0.86 | NPC1 (0.63) | MEN1KMT2ARAB9ANPC1CYP1A2 | |
| SCHEMBL856156 | 0.86 | MEN1 (0.56) | MEN1KMT2ARAB9ANPC1CYP1A2 | |
| SCHEMBL691596 | 0.85 | MEN1 (0.67) | MEN1KMT2ARAB9ANPC1CYP1A2 | |
| SCHEMBL2305280 | 0.84 | TP53 (0.74) | MEN1KMT2ARAB9ANPC1CYP1A2 | |
| Hydrochloric Acid SCHEMBL2176643 | 0.84 | NPC1 (0.61) | MEN1KMT2ARAB9ANPC1CYP1A2 | |
| SCHEMBL12487147 | 0.82 | NPC1 (0.64) | MEN1KMT2ARAB9ANPC1CYP1A2 | |
| SCHEMBL2173971 | 0.82 | EGFR (0.72) | MEN1KMT2ARAB9ANPC1CYP1A2 | |
| SCHEMBL2176219 | 0.82 | EGFR (0.67) | MEN1KMT2ARAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006783-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | MERCK PATENT GMBH (DE) | 2025-01-02 | — | — | WO | disclosed |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2022-02-22 | — | — | US | disclosed |
| US-8598171-B2 | Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20110312093-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-BETA PEPTIDE-RELATED DISORDERS | NETZER WILLIAM (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110275640-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2011-11-10 | — | — | US | disclosed |
| US-20110275641-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2011-11-10 | — | — | US | disclosed |
| US-20030199002-A1 | Clk-2 nucleic acids, polypeptides and uses thereof | MMV FINANCIAL INC. (CA) | 2003-10-23 | — | — | US | disclosed |
| WO-2003057165-A2 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2003-07-17 | — | — | WO | disclosed |
| EP-0733045-B1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | EP | disclosed |
| CN-1047778-C | Pyrimido [5-4-d] pyrimidines, drugs containing these compounds, their use and process for preparing them | THOMAE GMBH DR K (DE) | 1999-12-29 | — | — | CN | disclosed |
| US-5880130-A | TREATMENT OF CELL-PROLIFERATION DISEASES | ZENECA LIMITED (GB) | 1999-03-09 | — | — | US | disclosed |
| US-5880130-A | TREATMENT OF CELL-PROLIFERATION DISEASES | ZENECA LIMITED (GB) | 1999-03-09 | — | — | US | disclosed |
| EP-0779888-A1 | PYRIMIDO [5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | Dr. Karl Thomae GmbH (DE) | 1997-06-25 | — | — | EP | disclosed |
| EP-0733045-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996007657-A1 | PYRIMIDO[5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1996-03-14 | — | — | WO | disclosed |
| WO-1995015952-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR0B1, NR1H3, NCOA3 | MEN1 2424/4885KMT2A 2202/4885RAB9A 3526/4885 |
| US-20110275641-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | MEN1 2812/4885KMT2A 2224/4885RAB9A 2624/4885 |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | ALK, BRAF, MUSK | MEN1 1709/4885KMT2A 1403/4885RAB9A 3256/4885 |
| US-20110275640-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | MEN1 2812/4885KMT2A 2224/4885RAB9A 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.